The Latest in CLL

CLL boost in PFS came at high cost in side effects

March 8, 2017

CLL

CAR designers report high B-cell cancer response rates

March 2, 2017

Ublituximab was safe, highly active in rituximab-pretreated B-cell NHL, CLL

February 21, 2017

CLL

In CLL, specific mutation is key to ibrutinib resistance

February 13, 2017

CLL

In active CLL with deletion 17p, consider trial enrollment

February 9, 2017

CLL

Why CLL may go chemo free

February 8, 2017

CLL

AML leads percent gains in 5-year survival among leukemias

January 30, 2017

Lenalidomide maintenance extended progression-free survival in high-risk CLL

January 17, 2017

CLL

Ibrutinib continues to wow in CLL/SLL

January 11, 2017

CLL

Lenalidomide improves PFS after 1st and 2nd line CLL therapy

December 14, 2016

CLL

Idelalisib held unlikely to become frontline therapy for CLL

November 23, 2016

CLL

Targeted therapies predicted to blow out costs for CLL

November 21, 2016

CLL

Minimal residual disease status predicts 10-year survival in CLL

October 13, 2016

CLL

CD49d trumps novel recurrent mutations for predicting overall survival in CLL

October 13, 2016

CLL

Survival in CLL predicted by minimum residual disease

August 29, 2016

CLL